

Applicant: Raymond J. Bergeron, Jr.

Group Art Unit: 1614

Examiner: Not Yet Assigned

Title: Antioxidant and Radical Scavenging Activity of Synthetic Analogs of Desferrithiocin



CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:

2/18/04 Rachel Meehan
Date Signature

RACHEL MEEHAN
Typed or printed name of person signing certificate

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

This Information Disclosure Statement is submitted:

[X] under 37 CFR 1.97(b), or

[] under 37 CFR 1.97(c) together with either:

[] a \$180.00 fee under 37 CFR 1.17(p), or

under 37 CFR 1.97(d) together with:

☐ a \$180.00 fee under 37 CFR 1.17(p), or

[] under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)


Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references (AL, AM & AR-AZ) are enclosed.
- ☒ Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.
- ☐ Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☒ The listed references were cited in the enclosed Communication Relating to the Results of the Partial International Search (Form PCT/ISA/206) in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - ☐ the enclosed English language abstract.



☐ Applicant requests that the following non-published pending applications be considered:

Examiner's
Initials

____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

☐ A copy of each above-cited application, including the current claims, is enclosed.

☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.

☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Jesse A. Fecker
Jesse A. Fecker
Registration No.: 52,883
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: 2-18-04

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
2134.2009-001APPLICATION NO.
10/645,348FIRST NAMED INVENTOR
Raymond J. Bergeron, Jr.FILING DATE
August 21, 2003EXAMINER
Not Yet AssignedCONFIRMATION NO.
7060GROUP
1614INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

February 17, 2004

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AA	3,729,378	04-24-1973	Tomio Imai <i>et al.</i>
	AB	6,211,234 B1	04-03-2001	Astles <i>et al.</i>

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
	AL	WO 03/075910 A1	09-18-2003	Protemix Corporation Limited	
	AM	WO 00/16765	03-30-2000	University of Florida	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AR	Bergeron, R.J., <i>et al.</i> , "Methoxylation of Desazadesferrithiocin Analogues: Enhanced Iron Clearing Efficiency," <i>J. Med. Chem.</i> , 46: 1470-1477 (2003).
	AS	Bergeron, R.J., <i>et al.</i> , "Desferrithiocin Analogue Based Hexacoordinate Iron(III) Chelators," <i>J. Med. Chem.</i> , 46: 16-24 (2003).
	AT	Bergeron, R.J., <i>et al.</i> , "Prevention of Acetic Acid-Induced Colitis by Desferrithiocin Analogs in a Rat Model," <i>Digestive Diseases & Sciences</i> , 48(2): 399-407 (2003).
	AU	Ryoo, I.-J., <i>et al.</i> , "A New Cytotoxic Phenylthiazoline, 4-Methylaeruginoic Acid, From <i>Streptomyces</i> sp. KCTC 9303," <i>J. Antibiotics</i> , 50(3): 256-258 (1997).
	AV	Elliot, G.T., <i>et al.</i> , "In Vitro Antiproliferative Activity of 2'-(2-Hydroxyphenyl)-2'-Thiazoline-4'-Carboxylic Acid and Its Methyl Ester on L1210 and P388 Murine Neoplasms," <i>Cancer Chemother. Pharmacol.</i> , 21: 233-236 (1988).
	AW	Kicic, A., <i>et al.</i> , "The Desferrithiocin (DFT) Class of Iron Chelators: Potential as Antineoplastic Agents," <i>Anti-Cancer Drug Design</i> , 16: 195-207 (2001).

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION February 17, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 2134.2009-001		APPLICATION NO. 10/645,348	
	FIRST NAMED INVENTOR Raymond J. Bergeron, Jr.		FILING DATE August 21, 2003	
	EXAMINER Not Yet Assigned		CONFIRMATION NO. 7060	GROUP 1614

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AX	Bergeron, R.J., <i>et al.</i> , "The Desferrithiocin Pharmacophore," <i>J. Med. Chem.</i> , 37: 1411-1417 (1994).
	AY	Chaudhri, G., and Clark, I.A., "Reactive Oxygen Species Facilitate the in Vitro and in Vivo Lipopolysaccharide-Induced Release of Tumor Necrosis Factor," <i>J. Immunology</i> , 143(4): 1290-1294.
	AZ	Shindo, K.A., <i>et al.</i> , "Thiazostatin A and Thiazostatin B, New Antioxidants Produced by <i>Streptomyces Tolurosus</i> ," <i>J. Antibiotics</i> , 42: 1526-1529 (1989).

EXAMINER	DATE CONSIDERED
----------	-----------------